Telix Pharmaceuticals Has a Positive Outlook Despite High Uncertainty

Telix's focus is expanding Illuccix and Gozellix distribution and investing in its new product pipeline. Illuccix launched in April 2022 and was the second commercially available PSMA imaging agent for prostate cancer. The US Food and Drug Administration, or FDA, approved Gozellix, which is also a PSMA imaging agent for prostate cancer in March 2025. These two agents form the group’s “Two Product Strategy.”